Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.
Cardiff Oncology (CRDF) has an average rating of hold and mean price target of $4.17, according to a
Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing
2026-09-10. The following slide deck was published by Cardiff Oncology, Inc.
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesda
This is the newest page. Registered accounts read further back.